Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and
vomiting caused by emetogenic cancer chemotherapy in adolescent participants. Participants
treated with emetogenic cancer chemotherapies that include either cisplatin,
cyclophosphamide, or carboplatin, or participants who experienced nausea and/or vomiting when
treated with a previously administered chemotherapy regimen that is planned to be repeated
will be enrolled in this study. In the double-blind Part 1 of this study, enrolled
participants will be randomized to receive either aprepitant or standard therapy. In Part 2
of this study, enrolled participants will receive open-label aprepitant.